Lantheus Holdings, Inc. (LNTH) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Lantheus Holdings, Inc. (LNTH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Lantheus Holdings, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • Newly added risk: Loss of transitional pass-through payment status (TPT Status) for PYLARIFY as of December 31, 2024, impacting reimbursement and competitiveness
- • Most materially updated risk: CMS 2025 OPPS Rule unbundled diagnostic radiopharmaceutical payments, reducing PYLARIFY’s payment rate to below prior ASP-based amount, changing competitive dynamics
Lantheus Holdings, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$384M
▲ +1.4% YoY▲ +1.6% QoQ
Net Income
$28M
▼ -78.8% YoY▼ -64.7% QoQ
Gross Margin
57.9%
▼ -602bp YoY▼ -585bp QoQ
Operating Margin
11.4%
▼ -2396bp YoY▼ -1191bp QoQ
Net Margin
7.2%
▼ -2738bp YoY▼ -1360bp QoQ
ROE
2.5%
Total Assets
$2.3B
EPS (Diluted)
$0.46
▼ -74.6% YoY▼ -58.9% QoQ
Operating Cash Flow
$105M
▼ -39.9% YoY▲ +20.9% QoQ
Source: XBRL data from Lantheus Holdings, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Lantheus Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.